Headquartered in Watertown, MA Fiscal year ends December NASDAQ: IRON discmedicine.com
Disc Medicine (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company is building a portfolio of potentially first-in-class therapeutic candidates that target fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin (a GlyT1 inhibitor/heme synthesis modulator) in Phase 3 development for erythropoietic protoporphyria (EPP), selcodebart (DISC-0974, an anti-hemojuvelin antibody for hepcidin suppression) in Phase 2 for anemia of myelofibrosis and inflammatory bowel disease, and DISC-3405 (an anti-TMPRSS6 antibody for hepcidin induction) in Phase 2 for polycythemia vera and Phase 1b for sickle cell disease. The company has no approved products or revenue and is pre-commercial, funding operations through equity financing. Updated
Warren Buffett has purchased more of his favorite energy stock. A couple of biotech stocks and a recreational boat maker also saw sizable buys from insiders.
Monday's top analyst upgrades and downgrades included Activision Blizzard, Adobe, Caesars Entertainment, Corning, DocuSign, Park Hotels & Resorts, PayPal, Target, Trip.com, Twilio and UiPath.
Disc Medicine (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases.
The Wall Street consensus 12-month price target for IRON is $118.33.
